- Home
- CBRE vs KVUE Comparison
CBRE vs KVUE Comparison
Compare CBRE & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRE
- KVUE
- Stock Information
- Founded
- CBRE 1906
- KVUE 2022
- Country
- CBRE United States
- KVUE United States
- Employees
- CBRE N/A
- KVUE N/A
- Industry
- CBRE Real Estate
- KVUE Specialty Chemicals
- Sector
- CBRE Finance
- KVUE Consumer Discretionary
- Exchange
- CBRE Nasdaq
- KVUE Nasdaq
- Market Cap
- CBRE 41.3B
- KVUE 41.0B
- IPO Year
- CBRE 2004
- KVUE 2023
- Fundamental
- Price
- CBRE $136.06
- KVUE $21.05
- Analyst Decision
- CBRE Buy
- KVUE Buy
- Analyst Count
- CBRE 9
- KVUE 12
- Target Price
- CBRE $152.11
- KVUE $25.33
- AVG Volume (30 Days)
- CBRE 1.4M
- KVUE 18.7M
- Earning Date
- CBRE 07-29-2025
- KVUE 08-05-2025
- Dividend Yield
- CBRE N/A
- KVUE 3.90%
- EPS Growth
- CBRE 2.39
- KVUE N/A
- EPS
- CBRE 3.28
- KVUE 0.55
- Revenue
- CBRE $36,742,000,000.00
- KVUE $15,302,000,000.00
- Revenue This Year
- CBRE $14.60
- KVUE $2.94
- Revenue Next Year
- CBRE $9.27
- KVUE $3.51
- P/E Ratio
- CBRE $43.72
- KVUE $38.17
- Revenue Growth
- CBRE 13.15
- KVUE N/A
- 52 Week Low
- CBRE $86.19
- KVUE $17.67
- 52 Week High
- CBRE $147.75
- KVUE $25.17
- Technical
- Relative Strength Index (RSI)
- CBRE 69.90
- KVUE 33.63
- Support Level
- CBRE $134.35
- KVUE $20.69
- Resistance Level
- CBRE $140.59
- KVUE $21.34
- Average True Range (ATR)
- CBRE 2.89
- KVUE 0.40
- MACD
- CBRE 0.61
- KVUE 0.01
- Stochastic Oscillator
- CBRE 88.77
- KVUE 16.73
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About KVUE Kenvue Inc.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.